Related Experiment Video
Updated: Aug 23, 2025

A High Content Imaging Assay for Identification of Botulinum Neurotoxin Inhibitors
Published on: November 14, 2014
Neurotoxicity evoked by organophosphates and available countermeasures
Lenka Pulkrabkova1,2, Barbora Svobodova1,2, Jan Konecny1,2
1Faculty of Military Health Sciences, University of Defence, Trebesska 1575, Hradec Kralove, Czech Republic.
Abstract:
Organophosphorus compounds (OP) are a constant problem, both in the military and in the civilian field, not only in the form of acute poisoning but also for their long-lasting consequences. No antidote has been found that satisfactorily protects against the toxic effects of organophosphates. Likewise, there is no universal cure to avert damage after poisoning. The key mechanism of organophosphate toxicity is the inhibition of acetylcholinesterase. The overstimulation of nicotinic or muscarinic receptors by accumulated acetylcholine on a synaptic cleft leads to activation of the glutamatergic system and the development of seizures. Further consequences include generation of reactive oxygen species (ROS), neuroinflammation, and the formation of various other neuropathologists. In this review, we present neuroprotection strategies which can slow down the secondary nerve cell damage and alleviate neurological and neuropsychiatric disturbance. In our opinion, there is no unequivocal approach to ensure neuroprotection, however, sooner the neurotoxicity pathway is targeted, the better the results which can be expected. It seems crucial to target the key propagation pathways, i.e., to block cholinergic and, foremostly, glutamatergic cascades. Currently, the privileged approach oriented to stimulating GABAAR by benzodiazepines is of limited efficacy, so that antagonizing the hyperactivity of the glutamatergic system could provide an even more efficacious approach for terminating OP-induced seizures and protecting the brain from permanent damage. Encouraging results have been reported for tezampanel, an antagonist of GluK1 kainate and AMPA receptors, especially in combination with caramiphen, an anticholinergic and anti-glutamatergic agent. On the other hand, targeting ROS by antioxidants cannot or already developed neuroinflammation does not seem to be very productive as other processes are also involved.
Insights
Organophosphate poisoning causes severe neurotoxicity by inhibiting acetylcholinesterase. Targeting glutamatergic cascades, rather than reactive oxygen species, offers a promising neuroprotection strategy against lasting nerve damage.
Area of Science:
- Neuroscience
- Toxicology
- Pharmacology
Background:
- Organophosphorus (OP) compounds cause significant acute and chronic neurotoxicity.
- Current treatments lack efficacy in preventing OP-induced nerve damage.
- OP toxicity stems from acetylcholinesterase inhibition, leading to excitotoxicity and neuroinflammation.
Purpose of the Study:
- To review and present neuroprotection strategies against organophosphate toxicity.
- To identify effective therapeutic targets for mitigating OP-induced neurological damage.
- To evaluate current and potential interventions for organophosphate poisoning.
Main Methods:
- Review of existing literature on organophosphate neurotoxicity mechanisms.
- Analysis of neuroprotection strategies targeting cholinergic and glutamatergic systems.
- Evaluation of the efficacy of antioxidants and anti-inflammatory agents.
Main Results:
- Organophosphate toxicity involves acetylcholinesterase inhibition, acetylcholine accumulation, and subsequent glutamatergic excitotoxicity.
- Targeting glutamatergic pathways, particularly with agents like tezampanel and caramiphen, shows promise.
- Strategies focusing on reactive oxygen species (ROS) and neuroinflammation have yielded less productive results.
Conclusions:
- No single antidote effectively protects against all organophosphate toxic effects.
- Early intervention targeting key neurotoxic pathways, especially glutamatergic cascades, is crucial for neuroprotection.
- Antagonizing glutamatergic hyperactivity presents a more efficacious approach than current GABAergic strategies for OP-induced seizures and brain protection.
More Related Videos
10:30A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
15:05Functional Evaluation of Biological Neurotoxins in Networked Cultures of Stem Cell-derived Central Nervous System Neurons
Published on: February 5, 2015
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Prevention of Further Absorption of Poison
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...